Currently, the prevalence of vertebral pain syndromes in patients from United States and European countries ranges from 14 to 42%. In outpatient back pain occupy one of the leading positions as for the causes of the total complaints. Pain in the lumbosacral region remains one of the most common chronic pain syndromes; prevalence of chronic pain in the back and neck varies from 24 to 56.7%. Pain in the lower back occurs in 7-9 out of 10 members of the adult population, representing, together with acute respiratory diseases leading cause of temporary disability.
Zanaflex pharmacological action
Zanaflex is the drug representing the group of centrally acting muscle relaxants with the main active ingredient of tizanidine. The medication is mainly produced in the form of 2 mg or 4 mg tablets. The treatment of muscle relaxants begins with the common therapeutic dose and continues throughout the retention of pain. Generally, the treatment lasts for several weeks.
One of the most effective and safe drugs of this group is Sirdalud, the international non-proprietary name - tizanidine. It is proved that the painful muscle spasm addition to standard therapy, muscle relaxants, leads to a more rapid regression of pain, muscle tension and improve mobility of the spine. Clinical studies comparing monotherapy with combination therapy of NSAIDs NSAIDs and tizanidine, demonstrated the superiority of the latter in efficiency.
Zanaflex is primarily used in the following cases:
• Herniated Disc
• Increased muscle tone as a result of injury back
• The recovery period after spinal surgery
Once in the body of the patient, tizanidine excites several receptors in the spinal cord, which causes blockage of certain amino acids. As a result, the inhibition of propagation of excitation in the nerve endings going to muscular frame back. Therefore, the relaxation of the muscles occurs, getting them back to the natural state and decreasing pain caused by increased tone (restoring the passive and active motion in the spine as well).
To remove the painful muscle spasms appointed a dose of 2-4 mg 3 times a day. In severe cases, the dose of 4+ mg is prescribed.
In case of spastic muscle condition caused by neurological diseases, the dose of preparation should be defined individually, taking into account the response of the patient to receive the drug. The initial dose should not exceed 6 mg/day, the multiplicity of purposes – 3 times a day.
The dosage must be gradually increased at intervals of 3-4 days to 1 week. Optimal therapeutic effect is usually achieved at a dose of 12-24 mg/day, distributed into 3-4 doses at regular intervals. However, do not exceed a dose of 36 mg/day.
Caution should be exercised in the appointment of Zanaflex in patients with impaired renal function – for this group of patients an individualized selection of the dosing regimen is required.
Patients who are experiencing drowsiness while taking the medication at the beginning of treatment should avoid all activities requiring a high degree of attention concentration (driving vehicles, working with machinery, etc.).
The treatment course must be abandoned in case of hypersensivity to components of the preparation is observed. The safety of Zanaflex administration during pregnancy and lactation periods in women has not been studied; therefore, initiating the treatment is recommended only after a consultation with a treating doctor.